Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Cardiology

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2015.05.127PMID 26404748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease

  2014cited by this paper
• Association of Spironolactone Use With All-Cause Mortality in Heart Failure: A Propensity Scored Cohort Study

  2013cited by this paper
• Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

  2013cited by this paper
• Eplerenone: A Review of Its Use in Patients with Chronic Systolic Heart Failure and Mild Symptoms

  2013cited by this paper
• Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study

  2013cited by this paper
• Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension

  2012cited by this paper
• Aliskiren, ALTITUDE, and the implications for ATMOSPHERE

  2012cited by this paper
• Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF)

  2012cited by this paper
• Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Abstract 17379: The Incidence and Risk Associated with a Serum Potassium <4.0 Mmol/l in Patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction (HF-REF): Results from the Emphasis-HF Trial

  2012cited by this paper
• Eplerenone: is it time to add this drug to current heart failure therapy?

  2012influential reference
• Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

  2011cited by this paper
• Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics

  2011cited by this paper
• Aldosterone antagonists--last man standing?

  2011cited by this paper
• Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial

  2011cited by this paper
• Spironolactone Management of Resistant Hypertension

  2010cited by this paper
• Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)

  2008cited by this paper
• case-control study gastrointestinal events: population based Spironolactone and risk of upper

  2006cited by this paper
• Spironolactone and risk of upper gastrointestinal events: population based case-control study

  2006cited by this paper
• Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension

  2005cited by this paper
• Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal Impairment

  2005cited by this paper
• Effects of eplerenone versus losartan in patients with low-renin hypertension.

  2005cited by this paper
• The evolution of aldosterone antagonists.

  2004cited by this paper
• Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes

  2004cited by this paper
• Efficacy and Safety of the Selective Aldosterone Blocker Eplerenone in Japanese Patients With Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study

  2004cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study

  2004cited by this paper
• Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment

  2004cited by this paper
• Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.

  2004cited by this paper
• Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.

  2003cited by this paper
• Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential

  2003cited by this paper
• Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension

  2003cited by this paper
• Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.

  2003cited by this paper
• Eplerenone: A New Aldosterone Receptor Antagonist—Are the FDA's Restrictions Appropriate?

  2002cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients

  2002cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).

  1996influential reference
• Letter: Urea treatment of skin malignancies.

  1974cited by this paper
• Treatment of hypertension with spironolactone. Double-blind study.

  1966cited by this paper
• Relationship of Plasma Aldadiene Levels and Antimineralocorticoid Effects of Spironolactone in the Laboratory

  1964cited by this paper
• The effects of spironolactone and chlorthalidone on arterial pressure.

  1962cited by this paper
• Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.

  1955cited by this paper

• Central serous retinopathy: update on disease understanding and treatment.

  2026cites this paper
• Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024

  2026cites this paper
• The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction

  2026cites this paper
• Tackling Therapeutic Inertia on Mineralocorticoid Receptor Antagonist Adoption in Heart Failure

  2026cites this paper
• Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency.

  2026cites this paper
• Contemporary management of advanced chronic kidney disease: An evidence-based review.

  2025cites this paper
• Advancing Heart Failure Care: Breakthroughs and Emerging Strategies

  2025cites this paper
• Aldosterone: From Essential Tubular Regulator to Pathological Driver—Physiology, Disease, and Therapeutic Advances

  2025cites this paper
• Managing heart failure with reduced ejection fraction (HFrEF): Integrating SGLT2 inhibitors.

  2025cites this paper
• Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis

  2025cites this paper
• Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24

  2025cites this paper
• Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.

  2025cites this paper
• Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study

  2025cites this paper
• Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis: Eplerenone and Spironolactone for CSCR.

  2025cites this paper
• Advancing antihypertensive drug development

  2025cites this paper
• The Effect of the Higher Temperature and UVA Radiation on the Pharmaceutical Preparation Containing Spironolactone—EPR Examination

  2025cites this paper
• Chronic esaxerenone treatment improves vascular function and lowers peripheral arterial stiffness in patients with idiopathic hyperaldosteronism

  2025cites this paper
• Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.

  2025cites this paper
• In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics

  2025influential citation
• The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial

  2025cites this paper
• Amiloride: revisiting an old drug for resistant hypertension

  2025cites this paper
• Familial Hyperaldosteronism Type IV in a Mother-Daughter Pair.

  2025cites this paper
• Long-Term Eplerenone Treatment in Peripapillary Pachychoroid Syndrome: A Case Series

  2025cites this paper
• Design, synthesis, and evaluation of naphthalidinamide analogues as nonsteroidal mineralocorticoid receptor antagonists

  2025cites this paper
• Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

  2024cites this paper
• Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis

  2024cites this paper
• Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology

  2024cites this paper
• Systemic Estrogen Therapy and Thrombosis: A Call for Individualized Clinical Decision Making in the Acute Care Setting.

  2024cites this paper
• Polypharmacological profiling across protein target families and cellular pathways using the multiplexed cell-based assay platform safetyProfiler reveals efficacy, potency and side effects of drugs.

  2024cites this paper
• Comparative Analysis of The Effectiveness of Antihypertensive Therapy Including Spironolactone and Eplerenone in Patients With Essential Hypertension and Atrial Fibrillation.

  2024cites this paper
• Blood pressure targets, medication consideration and unique concerns in elderly hypertension IV: Focus on frailty, orthostatic hypotension, and resistant hypertension.

  2024cites this paper
• Heart Failure in Older People Part 2: Guideline-Directed Medical Therapy.

  2024cites this paper
• Nonsteroidal mineralcorticoid receptor antagonist finerenone: a new approach for drug therapy of chronic kidney disease

  2024cites this paper
• Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models

  2024cites this paper
• Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation

  2024cites this paper
• Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups

  2024cites this paper
• Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to attenuate hypertension

  2024cites this paper
• Establishment of a scoring model for predicting clinical outcomes in patients with unilateral primary aldosteronism after superselective adrenal artery embolization

  2024cites this paper
• Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation.

  2024cites this paper
• Spironolactone versus Eplerenone in Patients with Resistant Hypertension: A Systematic Review and Indirect Meta-analysis

  2024cites this paper
• Spironolactone Induces Vasodilation by Endothelium-Dependent Mechanisms Involving NO and by Endothelium-Independent Mechanisms Blocking Ca2+ Channels

  2024cites this paper
• Evidence for the druggability of aldosterone targets in heart failure: A bioinformatics and data science-driven decision-making approach

  2024cites this paper
• Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review

  2024cites this paper
• Management of Hypertension in Patients With Polycystic Ovarian Syndrome: A Mini-Review.

  2024cites this paper
• Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis

  2024cites this paper
• Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases

  2023cites this paper
• SGLT2 inhibitors: new kids on the block to control hyperkalemia.

  2023cites this paper
• Eplerenone for the Treatment of Chronic Recurrent Chorioretinopathy Centralis Serosa

  2023cites this paper
• Aldosterone and Aldosterone Synthase Inhibitors in Cardiorenal Disease.

  2023cites this paper
• Progress in the Treatment of Malignant Ascites.

  2023cites this paper
• Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society

  2023cites this paper
• Aldosterone synthase inhibitor “Baxdrostat” for resistant hypertension: A clinical approach or futuristic idea?

  2023cites this paper
• Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone

  2023cites this paper
• The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances

  2023cites this paper
• Role of aldosterone and mineralocorticoid receptor (MR) in addiction: a scoping review.

  2023cites this paper
• 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism

  2023cites this paper
• Management of hypertension in patients with cancer: challenges and considerations

  2023cites this paper
• Molecular pharmacology of mineralocorticoid receptor antagonists: the role of co-regulators.

  2023cites this paper
• Exploring the mechanism of action and efficacy of Shi-Pi-San in the treatment of ascites in cirrhosis based on intestinal microbiota

  2023cites this paper
• Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors

  2023cites this paper
• Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension

  2023cites this paper
• Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

  2023cites this paper
• Functional Outcomes and Safety Profile of Trans-Foveal Subthreshold Micropulse Laser in Persistent Central Serous Chorioretinopathy

  2023cites this paper
• Management of Heart Failure with Reduced Ejection Fraction.

  2023cites this paper
• From ligands to behavioral outcomes: understanding the role of mineralocorticoid receptors in brain function

  2023cites this paper
• The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure–HFrEF

  2023cites this paper
• The Idiosyncratic Efficacy of Spironolactone-Loaded PLGA Nanoparticles Against Murine Intestinal Schistosomiasis

  2023cites this paper
• Effect of eplerenone on aldosterone and von Willebrand factor levelsin patients with myocardial infarction and chronic kidney disease

  2022cites this paper
• Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine‐based delivery applications and future trends

  2022cites this paper
• Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• Hormonal Treatment of Acne and Hidradenitis Suppurativa in Adolescent Patients.

  2022cites this paper
• Research Progress on the Material Basis and Action Mechanism of LuQi Formula in Treating Heart Failure

  2022cites this paper
• Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy

  2022cites this paper
• The Pharmacological Treatment of Pediatric Vertigo

  2022cites this paper
• The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers

  2022cites this paper
• Morphological parameters predicting subthreshold micropulse laser effectiveness in central serous chorioretinopathy

  2022cites this paper
• A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice

  2022cites this paper
• Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet.

  2022cites this paper
• Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension

  2022cites this paper
• Thrombophilia and hormonal therapy in transgender persons: A literature review and case series.

  2022cites this paper
• An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook

  2022cites this paper
• Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood

  2022cites this paper
• Repurposable Drugs That Interact with Steroid Responsive Gene Targets for Inner Ear Disease

  2022cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease

  2022cites this paper
• The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension

  2022cites this paper
• Central serous chorioretinopathy: Treatment

  2022cites this paper
• Stellungnahme von BVA, DOG und RG zur Chorioretinopathia centralis serosa (CCS)

  2022cites this paper
• Increases in glucocorticoids are sufficient but not necessary to increase cooperative burrowing in Damaraland mole-rats.

  2021cites this paper
• Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.

  2021cites this paper
• Stellungnahme von BVA, DOG und RG zur Chorioretinopathia centralis serosa (CCS)

  2021cites this paper
• Drug–Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications

  2021cites this paper
• Approach to the Patient with Liver Disease

  2021cites this paper
• Antiandrogens and Androgen Inhibitors

  2021cites this paper
• Side effects, ADRs & ADEs of diuretics

  2021cites this paper
• Nonsteroidal mineralcorticoid receptor antagonists: Novel therapeutic implication in the management of patients with type 2 diabetes.

  2021cites this paper
• Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease

  2021cites this paper
• THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE

  2021cites this paper
• Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study

  2021cites this paper
• Aldosterone Blockade in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

  2021cites this paper
• Hepatocrinology

  2021cites this paper